Key Takeaways
- An unusual, margin-punishing quarter: EBITDA margins were crushed by high-cost inventory colliding with unexpected competitor price drops, but volumes grew 6% QoQ, which management reads as the first sign of recovery.
- The new plant is the whole story: Phase-1 at Pakhajan begins trials in October/November, commercializes early FY25, and large customers are already waiting for capacity that the current Vapi site cannot supply.
- Raw materials have likely bottomed: Prices fell 50-100% in some categories YoY, but management senses a floor and expects clarity after mid-September when summer vacations end.
- Phase-2 capex is gated behind utilization: No new investment until Pakhajan hits 70-75% utilization, which management pegs to the beginning of FY26, and the next phase will cost significantly less than the ~₹400 cr Phase-1 because shared infrastructure is already built.
- What to watch next quarter: Whether the margin recovery promised for H2 FY24 actually begins to materialize, the volume breakup disclosure that starts next quarter, and any signal from mid-September raw material price trends.
The Q1 Margin Shock
- High-cost inventory trap: The quarter carried raw material purchased at elevated prices into a market where competitors unexpectedly slashed selling prices, compressing spreads from both sides. Management called the quarter "unusual" and "very much unpredicted."
- Sentiment amplified the damage: Falling price expectations made buyers hesitant, which further pressured realizations on specialty products where demand was already limited.
- Recovery path is sequenced: Management wants to first repair the consumption ratio (raw material cost to sales), which deteriorated during the quarter, and only then focus on absolute EBITDA per ton. The 18% margin level is the initial target.
- H2, not Q2: Margin improvement is expected in the second half of FY24 for the legacy Vapi operations, not in the immediate next quarter.
Jhaveri: "I think the Q1 was very much, you can use the word unusual quarter, very much unpredicted, lot of high cost inventories there, unexpected price drop by the competitor of some part of the world and the sentiment, the prices are going down, so that has reduced the margin."
Volume Recovery Underneath the Revenue Decline
- Topline masks the turn: Revenue fell 16% YoY, but that was driven by collapsing raw material prices flowing through to selling prices, plus a YoY volume decline against a very strong Q1 FY23 base. Sequentially, volumes rose 6% QoQ.
- Export demand is split: Europe saw a drastic drop, and parts of Asia remain weak. North America, South America, and the Middle East have shown revival over the last two months.
- Raw material prices finding a floor: Management believes prices have bottomed out, with some categories beginning to stir. The summer vacation period across Europe and parts of Asia means real price discovery resumes only after mid-September.
Jhaveri: "we believe a kind of sense we are getting today that the pricings have been bottomed out looks like, we see somewhere some start in the certain category and if after the summer vacation which is now going on that is after somewhere in mid-September, we will have more clarity how strongly the..."
The Pakhajan Facility: Timeline and Ramp-Up
- Trials start October/November: Commercial production and revenue contribution begin only in early FY25, so the new facility adds zero topline in FY24.
- Year one will be modest: Management guided to 60-65% capacity utilization in the first year (FY25), explicitly stating that Q1 FY25 "will not be a robust" quarter. Full ramp-up takes time as customers validate products from the new site.
- 90% utilization targeted by FY26: Optimum utilization at the new facility is expected within two years of commercialization. Once achieved, management expects 20%+ minimum EBITDA margins at the consolidated level.
- Customers are waiting: Large customers have already approved products at the current Vapi site and are waiting for the new facility to begin production. Current capacity is the binding constraint. A couple of new customers, in contact for months, will audit the facility after receiving samples.
- Product mix kept opaque: Management declined to disclose the split between lubricants, rubber chemicals, and specialty chemicals at Pakhajan, calling it guidance they will not give.
Jhaveri: "we are giving guidance we can utilize between 60% and 65% in the capacity as even the Q1 of FY25 will not be a robust, but it will fully ramp up the sales from that facility."
Phase-2 Capex: Gated and Cheaper
- Trigger is 70-75% utilization at Pakhajan: Management has Phase-2 plans "in the drawing room" but will not discuss them publicly until the utilization threshold is met, which it expects around the beginning of FY26.
- Significantly lower investment needed: Phase-1 (~₹400 cr) included land development, an admin block, effluent treatment, utility blocks, and warehousing. Phase-2 requires only production equipment and building, so the capex will be materially smaller, though management declined to estimate the amount.
- Product direction unstated: When asked whether Phase-2 would extend the same product lines or enter new chemistries, management gave a general answer about company philosophy without specifying plans.
Jhaveri: "Once we achieve 70% to 75%, we always think about the next CAPEX, already we have plan in drawing room, but we don't talk about it unless and until we achieve there."
Vapi Operations and the Make-in-India Tailwind
- Utilization target above 95%: The legacy Vapi site (12,500 MT capacity) is expected to run near full in FY24, even as margins recover only in the second half.
- Make-in-India is converting to business: Government pressure on PSUs and large companies to use local components is generating more enquiries that are "transferring to reality step by step." The new plant should help Yasho capitalize on demand it currently cannot serve.
- Volume disclosure coming: Starting next quarter, management will provide a volume breakup between consumer and industrial segments in quarterly presentations, responding to an analyst request.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Margin recovery (Vapi operations) | Improvement from subdued Q1 levels, targeting 18% first | H2 FY24 |
| Vapi utilization | Above 95% of 12,500 MT capacity | FY24 |
| Pakhajan trials begin | Trials start; no revenue contribution in FY24 | October/November 2023 |
| Pakhajan commercialization | Commercial production begins | Early FY25 |
| Pakhajan Year 1 utilization | 60-65% capacity utilization | FY25 |
| Pakhajan optimum utilization | 90% minimum utilization | FY26 (within 2 years of commercialization) |
| Long-term consolidated EBITDA margin | 20%+ minimum | Once optimum utilization at Pakhajan is reached |
| Phase-2 capex decision | Revisit only after achieving 70-75% utilization at Pakhajan | Beginning of FY26 |
| Volume breakup disclosure | Consumer vs industrial segment breakup in quarterly presentations | Starting next quarter |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue from operations | Declined 16% YoY |
| Volume growth | Grew 6% QoQ (Q4 FY23 to Q1 FY24); declined YoY |
| EBITDA margin | 17%-18%, with target to improve to 20% plus |
| EBITDA per ton | ~₹1 lakh (per an analyst's math) |
| Industrial chemicals revenue share | Over 81% of total revenue |
| Total debt expected by FY24 | ~₹500 cr, including working capital |
| Phase-1 CAPEX at Pakhajan | ~₹400 cr, of which ~₹250 cr for land development and long-term CAPEX |
| Vapi capacity | 12,500 metric tons |
| Vapi utilization target for FY24 | Above 95% |
| Vapi utilization previous year | ~90% |
| New facility utilization target, first year | 60%-65% (early FY25) |
| New facility optimum utilization target | 90% minimum, expected by FY26 |
| New facility commercialization timeline | Early FY25, trials starting October/November |
| Raw material price decline | 50% to 100% in some categories |